您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > FPR2 agonist 2
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
FPR2 agonist 2
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
FPR2 agonist 2图片
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
FPR2 agonist 2 是一种有效的可透过血脑屏障的FPR2激动剂,h-FPR2EC50值为 0.13 μM。FPR2 agonist 2 抑制促炎细胞因子的产生,抵消线粒体功能的变化,并抑制 caspase-3 的活性。
生物活性

FPR2 agonist 2 is a potent and permeates the blood–brain barrierFPR2agonist with anEC50of 0.13 μM, 1.1 μM for FPR2 and FPR1, respectively. FPR2 agonist 2 inhibits the production of pro-inflammatory cytokines, counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity[1].

IC50& Target

EC50: 0.13 μM (FPR2); 1.1 μM (FPR1)[1]

体外研究
(In Vitro)

FPR2 agonist 2 (compound (S)-11l) (1-100 μM; 48 h) exhibits low cytotoxicity with an EC50value of 20.8 μM in N9 cells[1].
FPR2 agonist 2 (FPR1/FPR2 HL60 cells) shows agonist activity with EC50s of 0.13 μM, 1.1 μM (IC50s of 0.085 μM, Not determined) for FPR2 and FPR1, respectively[1].
FPR2 agonist 2 (0.1 μM) effectively blocks LPS-induced cell death and NO production and effectively suppresses the effect of LPS stimulation[1].
FPR2 agonist 2 (0.1 μM) counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity[1].

Cell Viability Assay[1]

Cell Line:N9 cells
Concentration:1-100 μM
Incubation Time:48 h
Result:Exhibited low cytotoxicity with an EC50value of 20.8 μM in N9 cells.
体内研究
(In Vivo)

FPR2 agonist 2 (1 mg/kg for i.v.; 10 mg/kg for i.p.) shows the ability to permeate the blood–brain barrier and to accumulate in the brain[1].

Animal Model:25-30 g, male CD-1 mice[1]
Dosage:
Administration:1 mg/kg for i.v.; 10 mg/kg for i.p. (dissolved in 5% DMSO, 10% solutol HS 15, and 85% sterile water)
Result:Showed the ability to permeate the blood–brain barrier and to accumulate in the brain.
分子量

446.45

Formula

C25H20F2N4O2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.